BerandaATHA • NASDAQ
add
Athira Pharma Inc
$0,29
Setelah Jam Perdagangan Normal:(5,00%)-0,015
$0,28
Tutup: 28 Apr, 17.18.01 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,28
Rentang hari
$0,27 - $0,30
Rentang tahun
$0,22 - $3,67
Kapitalisasi pasar
11,65Â jt USD
Volume Rata-Rata
188,28Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 15,57Â jt | -49,20% |
Laba bersih | -15,00Â jt | 45,01% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -15,32Â jt | 49,59% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 51,28Â jt | -65,22% |
Total aset | 58,78Â jt | -63,32% |
Total liabilitas | 13,94Â jt | -53,63% |
Total ekuitas | 44,84 jt | — |
Saham yang beredar | 39,04 jt | — |
Harga terhadap nilai buku | 0,25 | — |
Tingkat pengembalian aset | -53,67% | — |
Tingkat pengembalian modal | -74,16% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -15,00Â jt | 45,01% |
Kas dari operasi | -26,01Â jt | 1,06% |
Kas dari investasi | -2,81Â jt | -144,00% |
Kas dari pembiayaan | 34,00Â rb | -77,63% |
Perubahan kas bersih | -28,79Â jt | -45,78% |
Arus kas bebas | -12,30Â jt | 32,48% |
Tentang
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Didirikan
2011
Kantor pusat
Situs
Karyawan
26
